As enteroendocrine nutrient-sensing and the incretin axis are subjects of intense interest in drug discovery for metabolic disorders [30], future studies to determine the signaling mechanisms responsible for SCFAs' beneficial effects may have a major impact on the development of novel therapies for diabetes and obesity. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.